Commentary: Evaluating potential glioma serum biomarkers, with future applications

doi:10.5306/wjco.v13.i5.412

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4069)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

254

WORD

HTML

2097

Sum=2437

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

465

Download

1167

Sum=1632

May 24, 2022 (publication date) through Feb 16, 2026

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Clin Oncol. May 24, 2022; 13(5): 412-416
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.412

Commentary: Evaluating potential glioma serum biomarkers, with future applications

Michael Goutnik, Brandon Lucke-Wold

Michael Goutnik, Brandon Lucke-Wold, Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States

Author contributions: Goutnik M wrote the manuscript; Lucke-Wold B contributed to writing, and edited the manuscript.

Conflict-of-interest statement: The authors deny any conflicts of interest.

Corresponding author: Michael Goutnik, MS, Department of Neurosurgery, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, United States. mgoutnik@ufl.edu

Received: November 28, 2021
Peer-review started: November 28, 2021
First decision: February 15, 2022
Revised: March 15, 2022
Accepted: May 14, 2022
Article in press: May 14, 2022
Published online: May 24, 2022
Processing time: 176 Days and 19.7 Hours

Abstract

Systemic inflammation within malignant glioma is a topic of ongoing significance. In this commentary, we highlight recent findings from Gandhi et al and discuss alternative approaches. We present a counter argument with findings that IL-6 markers are controversial. We highlight the potential benefit of looking at microRNAs and other biomarkers. Finally, we present ideas for future application involving differentiation between radiation necrosis and recurrence. The commentary is intended to serve as a catalyst for further scientific discovery.

Keywords: Systemic inflammation; Malignant glioma; Neutrophil-lymphocyte ratio; Interleukin-6

Core Tip: Systemic inflammation in malignant glioma, along with the potential for blood-based biomarkers, is an exciting field of ongoing research. We have discussed supporting and contrasting evidence for glioma blood-based biomarkers, along with future research proposals.